Paris, France. May 28, 2020 – 6.00 PM CEST– Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, held Its General Meeting today in a closed session, which adopted all the proposed resolutions.

The General Meeting has approved the renewal of Mr. Bernard Gilly, Mr. Lloyd Diamond and Mr. Robert Ten Hoedt as Directors for three years, and the renewal of Kreos Capital as Observer also for three years.

The Board of Directors meeting has renewed the term of office of Mr. Bernard Gilly as Chairman of the Board for three years.

The Board of Directors of Pixium Vision is composed of the following members:

  • Mr Bernard Gilly, Chairman of the Board
  • Mr Lloyd Diamond, Chief Executive Officer and Director
  • BPIfrance Participations, represented by Mrs Olivia Le Proux de la Rivière, Director
  • Sofinnova Partners, represented by Mr Gérard Hascoët, Director
  • Mrs Marie Meynadier, Independent Director
  • Robert J. W. Ten Hoedt, Independent Director

• Kreos Capital V (Expert Fund) LTD, represented by Mr Aris Constantidines, Observer

Contacts

Pixium Vision
Didier Laurens
Chief Financial Officer
investors@pixium-vision.com
+33 1 76 21 47 68
Media relations

LifeSci Advisors
Sophie Baumont

sophie@lifesciadvisors.com
+33 6 27 74 74 49
Investor relation
LifeSci Advisors
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+33 6 69 99 37 83

 


Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information:  http://www.pixium-vision.com/fr

Follow us on @PixiumVision;  www.facebook.com/pixiumvision

              www.linkedin.com/company/pixium-vision 

 

Attachment